PCSK9 and ovarian carcinoma: It is possible that circulating cholesterol is not the cause of the observed relationship between HMG-CoA reductase inhibition and ovarian cancer due to the lack of genetically close inhibition between NPC1L1 and PCSK9 inhibition and genetically close LDL cholesterol levels (Yarmolinsky et al., 2020).